Drugs / RC017
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07521748 | Apr → Dec 2026 expected | dry eye syndrome | Nanjing Reju Therapeutics Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RC017 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07521748 ↗ |
| Modality | Small molecule | “RC017 is a small-molecule drug” NCT07521748 ↗ |